THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The required details are given in the reply to Starred Question No. 77 for 27th Februray, 1989.

(f) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

Exemption from Price Control of Small Scale Units

617. SHRI CH1TTA BASU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that small scale units are exempted from price control irrespective of sales turnover from Categ-ory-II formulations;

(b) whether it is also a fact that certain small scale units have turnover more than organised sector units;

(c) names of small scale units having annual sales turnover for more than ten crores;

(d) whether it is also a fact that his Ministry has shifted certain drugs from Category I to Category II;

(e) if so, what are the names of those drugs;

(f) whether it is a fact that Kelkar Committee recommended exemption of small scale units with turnover ceiling in the supplementary report;

(g) if so, what are the details thereof; and

(h) what is the position of drugs shifted under price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) and (c) Sales turnover is not monitored by this Ministry.

(d) and (e) Yes, Sir. The following drugs have been shifted from Category-I to Categroy-II of DPCO, 1987;

1. paracetamol.
2. Rifampicin.
3. Timolol.
4. Sulphacetamide Sodium.

(f) and (g) For the ptesent, the Government is not considering withdrawing of the exemption granted to SSI Units vide this Ministry Notificaiton No. S.O. 719(E) dt. 21.7.1988.

(h) The exemption from price control will also be available on such drugs to SSI Units, eligible for exemption from price control under the above said order.

Price Control on Paracetamol Formulations

618. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee recommended price decontrol on paracetamol in its initial report;

(b) on what basis this drug has been price controlled now on the basis of high concentration;

(c) whether **it** is a fact that none of the formulators account for more than 23 per cent of the market of the product;

(d) whether it is a fact that criteria of high concentration has been ignored in the case of Methdilazine, Gly-benelamide, Glipizide, Polymixin B Sulphate, Dulcolax and other medicines where 80 per cent of the market is controlled by one company; and

(e) what are the details of recommen-dations made in the supplementary report in respect of these drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO), (a) to (e) The required details, to the extent available, will be collected and laid on the Table of the House.

DPCO Impact

619. CHOWDHARY RAM SEWAK. Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news item which

appeared in the *Economic Times* on 27th January, 1989, under the heading of DPCO impact favourable;

(b) if so, what are the basis on which the control measured and how Chairman BICP have come to the conclusion that under DPCO, 1987, the span of price control has been reduced from 77 per cent to 73 per cent;

(c) what are the basis and details of data on which he drew the conclusion that price control has become less cumbersome and at the same time more effective;

(d) whether it is a fact that the methodology of price control remains the same and producer has to sell out more to sell his product *vis-a-vis* small scale; and

(e) whether it is a fact that the worst sufferer is the consumer?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a)' Yes, Sir.

(b) The required details, to the extent available, will be collected and laid on the Table of the House.

(c) It was made in the context of reduction in the number of drugs under DPCO, 1987 from DPCO>1979.

(d) The number of categories under control have been reduced from 3 to 2 improving the methodology.

(c) No. Sir.

Drugs and Formulations for Whole-sale Index

620. CHOV DHARY RAM SEWAK: Will the Mirister of INDUSTRY be pleased to sta^e:

(a) what are the names of -the bulk drugs and formu'ations in the basket of wholesale prio- index and when were they included;

(b) whether there is any proposal to review the basket and by when the basket would be reviewed:

(c) what was the wholesale price index of bulk drugs and formulations as in August, 1987. December, 1987 and December, 1988; and

(d) what is the weightage assigned to each bulk drug and formulations for the purpose of compiling the index?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) The required details to the extent available, will be collected and laid on the Table of the House.

Concentration of Formulation Market

621. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) whether the criterion of very high concenuai,,,., .a foiinuUiiuii market is a new criterion evolved by the Kelkar Committee;

(b) whether it is a fact that this criterion was not used in the initial report;

(c) if so, how drugs like Triprolidine. Polymixin B Sulphate. Flucinolone. Nandrolone Phenyl Propionate and Nan-drolone Decanoate were omitted from the list proposed for price control';

(d) what is the percentage control in the market "share that has been kept in view to determine the degree of concentration; and

(e) what are the names of drugs recommended for price control based on new criteria in the supplementary report?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (ej The required details, to the extent available, will be collected and laid on the Table of the House.

Filling wrong affidavits about Baralgon Ketone

622. SHRI ALADI ARUNA *alias* V. ARUNACHALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 23V given in